An internal standard for the quantification of nateglinide
Related Products
Unlabeled Version(s)
23320Nateglinide
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Nateglinide-d5

Item No. 30151

Technical Information
Formal Name
N-[[trans-4-(1-methylethyl)cyclohexyl]carbonyl]-D-phenylalanine-2,3,4,5,6-d5
CAS Number
1227666-13-8
Molecular Formula
C19H22D5NO3
Formula Weight
Purity
≥99% deuterated forms (d1-d5)
Formulation
A solid
Chloroform: slightly solubleMethanol: slightly soluble
SMILES
CC(C)[C@H]1CC[C@H](C(N[C@H](CC2=C([2H])C([2H])=C([2H])C([2H])=C2[2H])C(O)=O)=O)CC1
InChi Code
InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15-,16-,17-/m1/s1/i3D,4D,5D,6D,7D
InChi Key
OELFLUMRDSZNSF-LYGNPMIWSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Nateglinide-d5 is intended for use as an internal standard for the quantification of nateglinide (Item No. 23320) by GC- or LC-MS. Nateglinide is a hypoglycemic agent.1,2,3 It induces insulin and somatostatin release from perfused rat pancreas when used at concentrations ranging from 0.03 to 3 μM.1 Nateglinide (3 µM) increases intracellular calcium levels in isolated rat pancreatic β cells, an effect that can be inhibited by the L-type calcium channel blocker nitrendipine (Item No. 17549). Nateglinide-induced secretion of insulin and somatostatin and calcium influx is also reversed by the potassium channel activator diazoxide (Item No. 14576). Oral administration of nateglinide (1.6 mg/kg) reduces blood glucose levels by 20% in fasted mice.2 It also decreases blood glucose levels in an oral glucose tolerance test in normal rats, genetically diabetic KK mice, and a rat model of diabetes induced by streptozotocin (STZ; Item No. 13104).3 Formulations containing nateglinide have been used in the treatment of type 2 diabetes.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Fujitani, S., Ikenoue, T., Akiyoshi, M., et alSomatostatin and insulin secretion due to common mechanisms by a new hypoglycemic agent, A-4166, in perfused rat pancreas. Metabolism 45(2), 184-189 (1996).

    2. Shinkai, H., Toi, K., Kumashiro, I., et alN-acylphenylalanines and related compounds. A new class of oral hypoglycemic agents. J. Med. Chem. 31(11), 2092-2097 (1988).

    3. Sato, Y., Nishikawa, M., Shinkai, H., et alPossibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals. Diabetes Res. Clin. Pract. 12(1), 53-59 (1991).